(AQST) Aquestive Therapeutics - Ratings and Ratios
Film,Klaxx,Film,Sublingual,Epinephrine
AQST EPS (Earnings per Share)
AQST Revenue
Description: AQST Aquestive Therapeutics
Aquestive Therapeutics Inc (NASDAQ:AQST) is a pharmaceutical company with a diverse portfolio of products and a robust pipeline, focusing on central nervous system disorders and emergency treatments. The companys product portfolio includes Libervant for seizures, Suboxone for opioid dependence, Sympazan for Lennox-Gastaut syndrome, KYNMOBI for Parkinsons disease, and Azstarys for attention deficit hyperactivity disorder.
The companys pipeline includes promising products like Anaphylm, an epinephrine sublingual film in Phase 3 clinical trials for anaphylaxis treatment, and AQST-108, a topical gel in Phase 2 clinical trials for alopecia areata. Aquestives proprietary PharmFilm technology and Adrenaverse epinephrine prodrug platform further enhance its innovation capabilities.
To evaluate Aquestives performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and R&D pipeline progress are crucial. Notably, the companys Return on Equity (RoE) of 107.41% indicates a high return on shareholder equity. Additionally, the Market Cap of $337.71M USD suggests a moderate-sized company with potential for growth. The absence of a P/E ratio may indicate that the company is not yet profitable or has irregular earnings.
Analyzing the companys product portfolio and pipeline, we can identify potential opportunities for growth. For instance, the success of Anaphylm in Phase 3 clinical trials could significantly boost the companys revenue. Moreover, the development of AQST-108 and other pipeline products could expand Aquestives market presence. To capitalize on these opportunities, the company must effectively manage its R&D expenses, manufacturing costs, and commercialization strategies.
AQST Stock Overview
| Market Cap in USD | 656m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2018-07-25 |
AQST Stock Ratings
| Growth Rating | 28.8% |
| Fundamental | 32.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -14.9% |
| Analyst Rating | 4.56 of 5 |
AQST Dividends
Currently no dividends paidAQST Growth Ratios
| Growth Correlation 3m | 58.1% |
| Growth Correlation 12m | -26.9% |
| Growth Correlation 5y | -17.2% |
| CAGR 5y | 64.51% |
| CAGR/Max DD 3y | 1.02 |
| CAGR/Mean DD 3y | 2.08 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.14 |
| Beta | 0.772 |
| Volatility | 85.54% |
| Current Volume | 1277.7k |
| Average Volume 20d | 1330.7k |
| Stop Loss | 4.4 (-8.9%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-65.0m TTM) > 0 and > 6% of Revenue (6% = 2.65m TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -32.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 132.7% (prev 154.4%; Δ -21.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.53 (>3.0%) and CFO -49.7m > Net Income -65.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (99.3m) change vs 12m ago 9.26% (target <= -2.0% for YES) |
| Gross Margin 61.09% (prev 68.49%; Δ -7.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.77% (prev 49.62%; Δ -7.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.83 (EBITDA TTM -44.7m / Interest Expense TTM 17.0m) >= 6 (WARN >= 3) |
Altman Z'' -15.39
| (A) 0.63 = (Total Current Assets 81.7m - Total Current Liabilities 23.2m) / Total Assets 93.7m |
| (B) -4.27 = Retained Earnings (Balance) -399.7m / Total Assets 93.7m |
| warn (B) unusual magnitude: -4.27 — check mapping/units |
| (C) -0.46 = EBIT TTM -48.1m / Avg Total Assets 105.7m |
| (D) -2.40 = Book Value of Equity -399.6m / Total Liabilities 166.3m |
| Total Rating: -15.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.44
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -5.68% = -2.84 |
| 3. FCF Margin -81.39% = -7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.83 = -2.50 |
| 7. RoE data missing |
| 8. Rev. Trend -9.56% = -0.72 |
| 9. EPS Trend 10.03% = 0.50 |
What is the price of AQST shares?
Over the past week, the price has changed by -1.02%, over one month by +15.55%, over three months by +44.18% and over the past year by +0.84%.
Is Aquestive Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AQST is around 3.93 USD . This means that AQST is currently overvalued and has a potential downside of -18.63%.
Is AQST a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AQST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.8 | 81.8% |
| Analysts Target Price | 8.8 | 81.8% |
| ValueRay Target Price | 4.4 | -8.9% |
Last update: 2025-09-09 04:31
AQST Fundamental Data Overview
CCE Cash And Equivalents = 60.5m USD (Cash And Short Term Investments, last quarter)
P/S = 14.8572
Beta = 1.818
Revenue TTM = 44.1m USD
EBIT TTM = -48.1m USD
EBITDA TTM = -44.7m USD
Long Term Debt = 31.8m USD (from longTermDebt, last quarter)
Short Term Debt = 5.11m USD (from shortTermDebt, last quarter)
Debt = 37.0m USD (Calculated: Short Term 5.11m + Long Term 31.8m)
Net Debt = 65.7m USD (from netDebt column, last quarter)
Enterprise Value = 632.1m USD (655.7m + Debt 37.0m - CCE 60.5m)
Interest Coverage Ratio = -2.83 (Ebit TTM -48.1m / Interest Expense TTM 17.0m)
FCF Yield = -5.68% (FCF TTM -35.9m / Enterprise Value 632.1m)
FCF Margin = -81.39% (FCF TTM -35.9m / Revenue TTM 44.1m)
Net Margin = -147.4% (Net Income TTM -65.0m / Revenue TTM 44.1m)
Gross Margin = 61.09% ((Revenue TTM 44.1m - Cost of Revenue TTM 17.2m) / Revenue TTM)
Tobins Q-Ratio = -1.58 (set to none) (Enterprise Value 632.1m / Book Value Of Equity -399.6m)
Interest Expense / Debt = 11.57% (Interest Expense 4.28m / Debt 37.0m)
Taxrate = 21.0% (US default)
NOPAT = -48.1m (EBIT -48.1m, no tax applied on loss)
Current Ratio = 3.53 (Total Current Assets 81.7m / Total Current Liabilities 23.2m)
Debt / EBITDA = -0.83 (Net Debt 65.7m / EBITDA -44.7m)
Debt / FCF = -1.03 (Debt 37.0m / FCF TTM -35.9m)
Total Stockholder Equity = -59.8m (last 4 quarters mean)
RoA = -69.42% (Net Income -65.0m, Total Assets 93.7m )
RoE = unknown (Net Income TTM -65.0m / Total Stockholder Equity -59.8m)
RoCE = unknown (Ebit -48.1m / (Equity -59.8m + L.T.Debt 31.8m))
RoIC = unknown (NOPAT -48.1m, Invested Capital -26.6m, Ebit -48.1m)
WACC = 8.88% (E(655.7m)/V(692.6m) * Re(8.86%)) + (D(37.0m)/V(692.6m) * Rd(11.57%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 87.88 | Cagr: 5.80%
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -35.9m)
EPS Correlation: 10.03 | EPS CAGR: 109.7% | SUE: 0.38 | # QB: 0
Revenue Correlation: -9.56 | Revenue CAGR: -4.83% | SUE: -0.42 | # QB: 0
Additional Sources for AQST Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle